Moleculin Announces New Data Shows Reversal of Tumor Activity in Animal Models

HOUSTON, Dec. 19, 2019 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced the presentation of a poster entitled, “Liposomal annamycin inhibition of lung localized breast cancer,” at the San Antonio Breast Cancer Symposium held December 14 – 29, 2019.

The release as fetched from its publisher. moleculin.com ↗